2024-520019-41-00
CTIS ↗
Pharmacokinetic study of colistimethate sodium
serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options
pharma · infections · Not applicable (submitted trial is a BE study in healthy participants)
Zaklady FarmaFarmaceutyczne Polpharma
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
Zaklady FarmaFarmaceutyczne Polpharma trial registry — 6 ClinicalTrials.gov studies with program phase, status, and indication context.
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 6
- Drugs
- 15
- Patents
- 0
Zaklady FarmaFarmaceutyczne Polpharma clinical trials
Registry index of 6 ClinicalTrials.gov studies linked to Zaklady FarmaFarmaceutyczne Polpharma programs — each row shows trial ID, program name, phase, status, and indication.
Zaklady FarmaFarmaceutyczne Polpharma trial registry — 6 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Zaklady FarmaFarmaceutyczne Polpharma.
-
A single-dose for infection — Phase 1
Clinical update -
A single-dose for infections — Phase 1
Clinical update -
01-DAP-BIO-24 — Phase 1
Clinical update -
01-AMO-CLA-BIO-25 — Phase 1
Clinical update -
Pharmacokinetic study of colistimethate sodium — Phase 1
Clinical update -
Bioequivalence Study of Empagliflozin — Phase 1
Clinical update
Trial registry
-
- 2024-520212-18-00CTIS ↗
01-DAP-BIO-24
intended for treatment of for the treatment of (2): • insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. • symptomatic chronic heart failure. • chronic kidney disease.
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2026-525434-33-00CTIS ↗
Bioequivalence Study of Empagliflozin
Not applicable (submitted trial is a BE study in healthy participants)